NCLAT Reaffirms Patents Act's Primacy Over Competition Law in Patent Rights Disputes

NEW DELHI – In a significant ruling that reinforces the jurisdictional boundaries between intellectual property and competition law, the National Company Law Appellate Tribunal (NCLAT) has unequivocally affirmed that the Competition Commission of India (CCI) has no authority to investigate disputes arising from the exercise of patent rights. The tribunal held that such matters, including pricing and licensing of patented products, fall exclusively within the domain of the Patents Act, 1970.

The decision, delivered by a coram comprising Judicial Member Justice Yogesh Khanna and Technical Member Ajai Das Mehrotra, provides critical clarity on a long-standing legal debate. It solidifies the position that the Patents Act operates as a "self-contained code" for issues concerning patents, thereby ousting the jurisdiction of the CCI in such cases.

The ruling came in the case of Swapan Dey v Competition Commission of India and Anr , where the NCLAT dismissed an appeal filed against a 2022 CCI order. The original complaint had targeted Swiss pharmaceutical firm Vifor International (AG) over alleged anti-competitive practices related to its patented drug, Ferric Carboxymaltose (FCM).

The Heart of the Dispute: A Patented Drug and Allegations of Abuse

The case originated from a complaint by a hospital administrator who provides free dialysis services under a government health scheme. The complainant alleged that Vifor International was abusing its dominant position by selling FCM, a crucial drug for treating iron deficiency anaemia in dialysis patients, at an "unreasonably high price." This, it was argued, rendered the life-saving treatment unaffordable for many patients.

The complaint further contended that Vifor's licensing agreements with its Indian partners, Emcure Pharmaceuticals and Lupin Ltd., contained restrictive conditions that limited the drug's supply and stifled competition in the market.

In its 2022 decision, the CCI had investigated these claims but ultimately found no prima facie evidence of anti-competitive conduct. The Commission concluded that the terms of the licensing agreements did not suggest collusion or abuse of dominance, and therefore closed the case. The appellant subsequently challenged this closure order before the NCLAT.

NCLAT's Decisive Jurisdictional Stand

The NCLAT, however, bypassed the merits of the anti-competition allegations to address the fundamental question of jurisdiction. The tribunal held that the CCI was not empowered to conduct the investigation in the first place.

In its judgment, the appellate body stated, “It is apparent that the CCI lacks the power to examine the allegations made against Vifor International (AG). The Patent Act will prevail over the Competition Act in the facts of this case, as the subject matter of contention is FCM, which was developed and patented by Respondent No. 2.”

The tribunal’s reasoning was heavily anchored in established judicial precedents set by both the Delhi High Court and the Supreme Court of India. Citing the landmark Delhi High Court judgment in Telefonaktiebolaget LM Ericsson (PUBL) and the subsequent dismissal of the CCI's appeal by the Supreme Court (SLP No. 25026/2023), the NCLAT underscored the legal principle that the Patents Act is a special statute designed to govern all aspects of patent rights, including potential misuse.

The tribunal emphasized that when a product is protected by a patent, any grievances related to its pricing, licensing terms, or alleged abuse of rights must be adjudicated through the mechanisms provided within the Patents Act itself.

Vifor's Defence and the Role of the Patents Act

During the proceedings, Vifor International maintained that its actions were lawful and protected under the Patents Act. The company noted that its patent for the FCM molecule, granted in 2008, had expired in October 2023, after which other manufacturers were free to enter the market.

Vifor's counsel invoked Section 3(5) of the Competition Act, 2002, which provides a safe harbour for intellectual property rights holders. This provision exempts a patentee from allegations of anti-competitive agreements for imposing "reasonable conditions" necessary to protect their rights. The company argued that the CCI had no jurisdiction to scrutinize actions that are expressly permitted and regulated by a separate, specialized statute.

Legal Implications: A Clear Line in the Sand

This NCLAT ruling serves as a powerful precedent, drawing a clear jurisdictional line between two complex and often overlapping legal fields.

1. Strengthening the 'Special Law Prevails' Doctrine: The judgment robustly applies the doctrine of generalia specialibus non derogant (general things do not derogate from special things). It establishes the Patents Act as the specialized code for patent-related issues, which cannot be encroached upon by the Competition Act, a law of general application.

2. Clarity for Patent Holders: For pharmaceutical, technology, and other innovation-driven industries, this decision provides significant assurance. It clarifies that the legitimate exercise of patent rights, including setting prices and structuring license agreements, will be assessed under the specific provisions of patent law, which are designed to balance innovation incentives with public access.

3. Shift in Remedial Avenues: The ruling effectively redirects the path for complainants alleging misuse of patent rights. Instead of approaching the CCI for abuse of dominance, aggrieved parties will now have to primarily rely on remedies within the Patents Act, such as seeking a compulsory license from the Controller of Patents under Chapter XVI of the Act.

4. Impact on CCI's Scope: The decision curtails the CCI's investigative ambit in sectors heavily reliant on intellectual property. While the Commission retains its power to investigate anti-competitive conduct like cartels or bid-rigging, its authority to scrutinize the unilateral conduct of a patent holder related to the patent itself is now significantly limited.

By reaffirming the primacy of the Patents Act, the NCLAT has not only settled the immediate dispute but also contributed to a more predictable legal environment for the interplay between innovation and competition in India.